Jack Wallace
Stock Analyst at Guggenheim
(3.14)
# 1,104
Out of 5,245 analysts
21
Total ratings
57.89%
Success rate
273.86%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $160.17 | +55.46% | 4 | Oct 1, 2024 | |
| WW WW International | Maintains: Buy | $12 → $6 | $12.79 | -53.09% | 3 | Aug 2, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $23.75 | -28.42% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $1.29 | +989.49% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $167.90 | +31.03% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $8.92 | +348.43% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.96 | +1,156.28% | 1 | Mar 15, 2023 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $160.17
Upside: +55.46%
WW International
Aug 2, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $12.79
Upside: -53.09%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $23.75
Upside: -28.42%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $1.29
Upside: +989.49%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $167.90
Upside: +31.03%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $8.92
Upside: +348.43%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.96
Upside: +1,156.28%